CereMark Pharma, LLC is a West Virginia Limited Liability Company with headquarters in Wheeling WV and an office in Lexington KY. It is a developmental and clinical stage pharma company that focuses upon neurodegenerative diseases, including early diagnosis and management, as well as preventative, non-invasive management of chronic neurological impairment from events associated with traumatic brain injury.
CereMark Pharma is privately-held with 100% ownership by company founders and officers.
Flornaptitril F-18, our unique PET imaging radiopharmaceutical, is primed for the Phase 3 clinical investigative trial as a tool to better aid prediction of worsening mental impairment in individuals presenting with mild-moderate cognitive status.
Our therapeutic portfolio consists of early stage pre-clinical molecules that have shown to significantly improve the resultant memory loss, physical performance and neuro cellular status from traumatic brain injuries in animal models.